Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 15/20 | 0.65 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.49 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.49 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.49 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.49 |
| ▸ | KDR | P35968 | 1/20 | 0.49 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.47 |
| ▸ | GPR142 | Q7Z601 | 2/20 | 0.45 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3757765 | 0.90 | PIK3CA (0.79) | PIK3CA | |
| SCHEMBL3753626 | 0.88 | PIK3CA (0.79) | PIK3CA | |
| SCHEMBL3756495 | 0.86 | PIK3CA (0.57) | PIK3CACREBBPABCB1 | |
| SCHEMBL3748463 | 0.86 | PIK3CA (0.64) | PIK3CACREBBP | |
| SCHEMBL3762634 | 0.85 | PIK3CA (0.63) | PIK3CAGPR142 | |
| SCHEMBL3761198 | 0.85 | PIK3CA (0.65) | PIK3CAGPR142 | |
| SCHEMBL2726184 | 0.85 | PIK3CA (0.71) | PIK3CACREBBPGPR142 | |
| SCHEMBL3752730 | 0.84 | PIK3CA (0.66) | PIK3CACREBBP | |
| SCHEMBL3752244 | 0.83 | PIK3CA (0.68) | PIK3CACREBBP | |
| SCHEMBL3753766 | 0.83 | PIK3CA (0.65) | PIK3CACREBBP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100305093-A1 | Inhibitors of mTOR and Methods of Making and Using | EXELIXIS, INC. (US) | 2010-12-02 | — | — | US | disclosed |
| US-20100305093-A1 | Inhibitors of mTOR and Methods of Making and Using | EXELIXIS, INC. (US) | 2010-12-02 | — | — | US | disclosed |
| US-20100305093-A1 | Inhibitors of mTOR and Methods of Making and Using | EXELIXIS, INC. (US) | 2010-12-02 | — | — | US | disclosed |
| WO-2010118208-A1 | BENZOXAZEPIN-4- (5H) -YL DERIVATIVES AND THEIR USE TO TREAT CANCER | EXELIXIS, INC. (US) | 2010-10-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100305093-A1 | Inhibitors of mTOR and Methods of Making and Using | MTOR, RICTOR, RPTOR | PIK3CA 16/4885FGFR1 240/4885FGFR2 444/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.